DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Eptifibatide
OtherFDA approvedRx required

Eptifibatide

Also known as: Integrilin
Brands: Integrilin

Cyclic heptapeptide glycoprotein IIb/IIIa inhibitor used as an antiplatelet during PCI and acute coronary syndromes.

A
Grade A
Multiple human RCTs
Human studies25
PubMed citations29
Routeintravenous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Synthetic cyclic heptapeptide derived from a snake-venom disintegrin. Reversible GP IIb/IIIa receptor antagonist; blocks fibrinogen binding and platelet aggregation.

Evidence summary

25
Human studies
29
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
intravenous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for acute coronary syndromes and PCI (Integrilin)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07347626Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled TrialNot Yet Recruiting · Phase 3 · Acute Ischemic Stroke · n=786NCT03735979Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic StrokeCompleted · Phase 3 · Acute Ischemic Stroke · n=514NCT00089895Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)Completed · Phase 3 · Myocardial Ischemia · n=9406NCT05415150MEASUREMENT OF MARKERS OF PLATELET AGGREGATION AND INFLAMMATION IN ISCHEMIC STROKE SUBJECTS AFTER FIBRINOLYTIC/ANTI-THROMBOTIC USE. A PILOT STUDY.Unknown · Phase 1 · Acute Ischemic Stroke · n=30NCT01991366Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?Withdrawn · ST-elevation Myocardial InfarctionNCT01522417A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary InterventionCompleted · Phase 2 · Myocardial Infarction · n=535NCT02925923The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary InterventionCompleted · Phase 2 · Acute Coronary Syndrome · n=100NCT03844594Safety and Efficacy of Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke: a Single-arm, Open-label, Multicenter Clinical TrialUnknown · Phase 3 · Acute Ischemic Stroke · n=220NCT01103440A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary InterventionCompleted · Phase 2 · Stable Angina · n=36NCT03383393Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECGUnknown · Coronary Ischemia · n=60NCT02204852Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated TrialCompleted · Phase 2 · Septic Shock · n=18NCT01919723Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary InterventionCompleted · Phase 2 · Acute Coronary Syndrome · n=70

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 40921868Gothelf I, Arie GB et al. · Safety and Efficacy of Intracranial Stenting in Acute Stroke Patients Using a Pharmacological Treatment Protocol Including Low-Dose Intra-arterial Eptifibatide-A Single-center Retrospective Analysis.Clinical neuroradiology (2026)HumanPMID 40824660Rines I, Adeoye O et al. · Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical Trial.JAMA neurology (2026)PMID 41071964Roy A, Elm J et al. · Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.Neurology (2025)HumanPMID 40269739Shi S, Ling Z et al. · Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience.BMC cardiovascular disorders (2025)HumanPMID 39818980Dupont S, Lebas H et al. · Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage.Journal of the American Heart Association (2025)HumanPMID 39231343Adeoye O, Broderick J et al. · Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.The New England journal of medicine (2024)HumanPMID 37884759Huffman T, Gleaves E et al. · Delayed-onset eptifibatide-induced thrombocytopenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2024)HumanPMID 36561618Luo L, Lin J et al. · Treatment of progressive ischemic stroke with low‑dose eptifibatide: A retrospective case‑control study.Experimental and therapeutic medicine (2022)PMID 35255052Yun AN, Toyoda AY et al. · Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.Journal of cardiovascular pharmacology (2022)HumanPMID 32721916Petrovic SS, Vasiljevska MM et al. · Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology (2021)HumanPMID 30646761Van Tuyl JS, Newsome AS et al. · Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.The Annals of pharmacotherapy (2020)HumanPMID 31137917Lazarovici P, Marcinkiewicz C et al. · From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs.Toxins (2020)HumanPMID 31122865Caldeira D, Pereira H · Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review.Revista portuguesa de cardiologia (2019)HumanPMID 28184261Song JW, Soh S et al. · Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications.Korean journal of anesthesiology (2019)PMID 28449419Zhou X, Wu X et al. · Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.Journal of evidence-based medicine (2018)HumanPMID 27798792Waldron NH, Dallas T et al. · Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients.Journal of thrombosis and thrombolysis (2017)HumanPMID 25082819Brinjikji W, Morales-Valero SF et al. · Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.AJNR. American journal of neuroradiology (2016)HumanPMID 25120366Pasala T, Sattayaprasert P et al. · Clinical and economic studies of eptifibatide in coronary stenting.Therapeutics and clinical risk management (2014)PMID 22053759Ji X, Hou M · Novel agents for anti-platelet therapy.Journal of hematology & oncology (2012)HumanPMID 18078431Zeymer U, Wienbergen H · A review of clinical trials with eptifibatide in cardiology.Cardiovascular drug reviews (2008)Human

Showing 20 of 29 papers. View all on PubMed →